Tony Xue

Dr. Xue has more than 10 years of experience in the R&D, production, and domestic & international cooperation of biotechnology drugs, innovative small molecule drugs, and ADC drugs. Management: With more than 1,000 people of management experience, covering the design and screening of macromolecular and small molecule drugs, process development and scale-up, pharmacology and toxicology research, clinical development, production, and the company's transnational operations. Project development: including biosimilars and different types of innovative drugs, 2 varieties have been successfully launched, and more than 10 projects are in different stages of clinical trials, many of which are simultaneously conducting clinical trials in China and the United States. In terms of ADCs, different generations of technologies and different types of targets are involved, including HER2, TROP2, etc., as well as a series of more innovative targets. Intellectual property rights: more than 100 applications, involving China, the United States, Europe and other countries and regions, of which nearly 20 have been authorized. Business cooperation: reached a number of external licensing cooperation, involving more than 1 billion US dollars.